Inclusion Criteria:  Age ≥18 years and ≤80 years, regardless of gender; De novo lesion in a native coronary artery; Stable angina, or unstable angina, or old myocardial infarction or asymptomatic myocardial ischemia; Reference vessel diameter is 2.75mm-4.0mm with diameter stenosis ≥70% or ≥50% (with evidence of ischemia) and TIMI flow ≥1; The subject can receive any type of coronary vascular revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting); The subject who can understand the purpose of the trial, voluntarily participate in and sign an informed consent form, and is willing to accept clinical follow-up.  Exclusion Criteria:  Reference vessel diameter <2.75 mm or >4.0 mm; In stent restenosis; Left main lesion, chronic complete occlusion lesion; Ostial lesion ≤2mm from the LM, or bifurcation lesion with branch vessel diameter≥2.5mm; There is a large scale of thrombus in the target vessel, and the thrombus grade >3 after thrombolysis or aspiration; Severe heart failure (NYHA IV); Severe renal failure (GFR<30ml/min) or undergoing hemodialysis treatment; Severe liver failure (bilirubin is over 2 times the upper limit of normal, or alanine aminotransferase is over 3 times the upper limit of normal); Patients with vein graft restenosis after bypass or severe heart valve disease; Pregnant or breastfeeding female patients; The life expectancy of the patient is less than 12 months; The subject cannot be treated with anticoagulation because of bleeding tendency, history of active peptic ulcer, stroke in the 6 months before surgery, anti-platelet agents or anticoagulant treatment contraindications; Anemia (women's hemoglobin <117g/L, or men's hemoglobin <134g/L), or thrombocytopenia detected before the intervention within 6 months (<100×10⁹/L); Planned to perform non-cardiac surgery within 12 months after index procedure; The subject who participated in other clinical trials of drugs or instruments and did not reach time of primary endpoint; Heart transplant patients; Allergic to aspirin, clopidogrel, heparin, contrast agents, or paclitaxel; The investigator judged that the patient had poor compliance and could not complete the study as required.